NCT04274595View on ClinicalTrials.gov

Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

November 29, 2021

Study Completion Date

June 20, 2022

Conditions
Psoriasis
Interventions
DRUG

Generic antiretroviral

200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days

Trial Locations (2)

30029

CHU de Nimes, Nîmes

34295

CHU de Montpellier, Montpellier

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT04274595 - Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis | Biotech Hunter | Biotech Hunter